Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participant must be at least 18 years of age inclusive, at the time of signing the informed consent.~* Patients with primary hypercholesterolemia.~* Inclusion criteria in the run-in period: Participants who are not adequately controlled (defined by screening LDL-C \>2.6 mmol/L (100 mg/dL) and ≤4.9 mmol/L (190 mg/dL)with a 10 mg stable daily dose of rosuvastatin, or equipotent statin for 4 weeks prior to the screening visit, without any other lipid modifying therapy (LMT). Inclusion criteria in the randomized double-blind period: Participants who are not adequately controlled based on sample taken at qualifying pre randomization visit, despite stabilized dose of rosuvastatin 10 mg (defined by measured LDL-C ≥2.6 mmol/L (100 mg/dL) and ≤4.9 mmol/L (190 mg/dL).~* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.~* Capable of giving signed informed consent.~Exclusion criteria:~* Homozygous familial hypercholesterolemia (FH) (clinically or previous genotyping).~* Patient who has received LDL-C plasmapheresis treatment within 2 months prior to the screening visit, or has plans to receive it during the study.~* Recently diagnosed (within 3 months prior to the screening visit) myocardial infarction (MI), unstable angina, myocardial revascularization (percutaneous coronary intervention \[PCI\], coronary artery bypass graft surgery \[CABG\]), transient ischemic attack (TIA), or stroke, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease.~* Planned to undergo scheduled PCI, CABG, carotid or peripheral revascularization during the study.~* Severe hypertension (treated or untreated) with systolic blood pressure (SBP) \>160 mm Hg or diastolic blood pressure (DBP) \>100 mm Hg at study entry.~* History of severe congestive heart failure (New York Heart Association Class IIIb or IV) within the past 12 months.~* Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins, according to Investigator's medical judgement.~* Uncontrolled (as determined by fasting glucose \>180 mg/mL or HbA1c \>9%) or newly diagnosed (within 3 months of study entry) diabetes mellitus at the screening visit.~* History of cancer within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.~* Conditions/situations such as:~  * Patient with a short life expectancy.~ * Patient with conditions/concomitant diseases making them non-evaluable for the primary efficacy endpoint, according to Investigator's medical judgement.~ * Requirement for concomitant treatment that could bias primary evaluation, according to Investigator's medical judgement.~ * Impossibility to meet specific protocol requirements (eg, ability to make study visits).~ * Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the study.~ * Patient not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or patients potentially at risk of noncompliance to study procedures.~* Known history of hypersensitivity reaction to statins and/or ezetimibe.~* Current myopathy.~* A history of statin-induced myopathy or rhabdomyolysis.~* Current active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 x upper limit of normal (ULN) range at the screening visit.~* All contraindications to the active comparator (rosuvastatin) and background therapies or warning/precaution of use (when appropriate) as displayed in the respective National Product Labeling.~* Patients not previously instructed on a cholesterol-lowering diet prior to the screening visit.~* Use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to screening visit.~* Use of hormone replacement therapy or oral contraceptives unless regimen has been stable in the past 6 weeks prior to the screening visit and no plans to change the regimen during the study.~* Concomitant administration of cyclosporine (at screening and randomization visits).~* Human immunodeficiency virus (HIV) patients receiving protease inhibitors (at screening and randomization visits).~* Patient who has taken any active investigational drugs (E10/R10) within 1 month or 5 half-lives prior to screening, whichever is longer.~* Laboratory findings obtained during the screening visit (V1):~  * Fasting serum TGs \>400 mg/dL.~ * Positive serum pregnancy test.~ * Serum creatine kinase \>3 times ULN.~ * Thyroid-stimulating hormone (TSH) \< lower limit of normal (LLN) or \> ULN.~ * Glycated hemoglobin A1c (HbA1c) \>9%.~ * Estimated glomerular filtration rate \<30 mL/min/1.73 m2.~ * Alanine aminotransferase or AST \>3 x ULN.~* Individuals accommodated in an institution because of regulatory or legal order; prisoners or subjects who are legally institutionalized.~* Any technical/administrative reason (eg, patient homeless) that makes it impossible to enroll/randomize the patient in the study.~* Alcohol abuse according to Investigator's medical judgement.~* Participants are dependent on the Sponsor or Investigator (in conjunction with Section 1.61 of the ICH-GCP Ordinance E6).~* Participants are employees of the clinical study site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals.~* Any specific situation during study implementation/course that may rise ethics considerations.~* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single pill combination (SPC) (Type: EXPERIMENTAL): Once daily rosuvastatin 10 mg for 4 weeks, then once daily SPC ezetimibe 10 mg /rosuvastatin 10 mg (E10/R10) for 8 weeks
- Rosuvastatin (Type: ACTIVE_COMPARATOR): Once daily rosuvastatin 10 mg for 4 weeks, then once daily rosuvastatin 10 mg (R10) for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete